¸íÁöº´¿ø The 3nd MYONGJI INTERNATIONAL LIVER SYMPOSIUM : 2018-09-07±³À°ÀÏÀÚ : 2018-09-07
±³À°Àå¼Ò : ¸íÁöº´¿ø ³óõȦ
±³À°ÁÖÁ¦ :
The 3nd MYONGJI INTERNATIONAL LIVER SYMPOSIUM ÁÖÃÖ±â°ü :¸íÁöº´¿ø
´ã´çÀÚ : ÀÌÀåÇö
¿¬¶ôó : 031-810-5024
À̸ÞÀÏ :
jasonuranos@mjh.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
°æ±âµµ±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 13:00~13:30 Á¢¼ö ¹× Àλ縻 Prof. Hyo-Suk Lee(Myongji Hospital Goyangsi Korea)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 13:30~13:45 Changing Epidemiology: Increasing burden of non-B, non-C liver diseases in Korea Prof. Young-Suk Lim(Asan Medical Center Seoul Korea)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 13:45~14:00 Changing Epidemiology: Increasing burden of non-B,non-C liver diseases in Japan Prof. Junko Tanaka(Hiroshima University Hiroshima Japan)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 14:00~14:15 Changing Epidemiology: Increasing burden of non-B,non-C liver diseases in USA Prof. W. Ray Kim(Stanford University Palo Alto USA)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 14:15~14:30 Comparison of practice guidelines of NAFLD between AASLD 2017, EASL 2016 and Asia-Pacific Working Party 2017; similarities and differences Prof. Hitoshi Yoshiji(Nara Medical University Nara Japan)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 14:30~14:45 Characteristics of NASH-associated HCC and its clinical impacts in Korea Dr. Eun Ju Cho(Seoul National University Seoul Korea)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 14:45~15:00 Characteristics of NASH-associated HCC and its clinical impacts in Japan Dr. Soo Ki Kim(Kobe-Asahi Hospital Kobe Japan)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 15:00~15:15 Characteristics of NASH-associated HCC and its clinical impacts in USA Prof. W. Ray Kim(Stanford University Palo Alto USA)
ÈÞ½Ä 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 15:15~15:30 Coffee Break ()
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 15:30~15:45 Changing epidemiology of acute viral hepatitis: Hepatitis E in Korea Prof. Sook Hyang Jeong(Seoul National University Bundang Hospital Seongnam Korea)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 15:45~16:00 Changing epidemiology of acute viral hepatitis: Hepatitis E in Japan Dr. Jong-Hon Kang(Teine Keijinkai Hospital Sapporo Japan)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 16:00~16:20 Liver Immunology: Immunotherapy of HCC vs transplantation tolerance - Immunotherapy of HCC with check-point inhibitors Dr. Su Jong Yu(Seoul National University Seoul Korea)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 16:20~16:40 Liver Immunology: Immunotherapy of HCC vs transplantation tolerance - Operational transplantation tolerance with Treg cell therapy Prof. Hideki Ohdan(Hiroshima University Hiroshima Japan)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 16:40~17:00 Systemic therapy of HCC on the horizon other than check-point inhibitors - Oncolytic virotherapy of HCC: Pros and cons Prof. Takeshi Yamada(University of Tsukuba Tsukuba Japan)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 17:00~17:30 Approach to the risk and prevention of HCC in the era of precision medicine - Is the time ripe for application of GWAS in clinical hepatology? Prof. Naoya Kato(Chiba University Chiba Japan)
±³À°½Ã°£ 09¿ù 07ÀÏ ¸íÁöº´¿ø ³óõȦ 17:30~17:45 Summary of the 3rd MILS Prof. W. Ray Kim(Stanford University Palo Alto USA)